eFFECTOR Therapeutics, Inc.
EFTR · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 81.5% | – | – |
| R&D Expenses | $5 | $6 | $5 | $5 |
| G&A Expenses | $3 | $3 | $3 | $3 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $8 | $9 | $8 | $8 |
| Operating Income | -$8 | -$9 | -$8 | -$8 |
| % Margin | – | -5,306.8% | – | – |
| Other Income/Exp. Net | -$0 | -$1 | -$0 | -$1 |
| Pre-Tax Income | -$9 | -$9 | -$8 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$9 | -$8 | -$8 |
| % Margin | – | -5,635.2% | – | – |
| EPS | -3.31 | -3.42 | -3.36 | -4.37 |
| % Growth | 3.2% | -1.8% | 23.1% | – |
| EPS Diluted | -3.31 | -3.42 | -3.36 | -4.37 |
| Weighted Avg Shares Out | 3 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$8 | -$8 | -$8 |
| % Margin | – | -5,149.4% | – | – |